Analysts have turned bearish on CanSino Biologics, slashing next year's revenue estimates and predicting losses. Despite downgrades, they still foresee CanSino outpacing the broader industry.
Despite boasting a strong balance sheet, the company's future financial stability is questionable due to the negative free cash outflow of CN¥1.9b over the past 12 months and inconsistencies in free cash flow production.
Specifically, a second booster shot will be administered to people from high-risk groups, citizens older than 60, patients with chronic fundamental diseases and those with compromised immune systems. Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up.$康希諾生物(06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million.$RECBIO-B(02179.HK)$,$諾誠健華医薬(09969.HK)$and ...
$康希諾生物(06185.HK)$price is up on speculation cansino inhaler ( whole 1st Covid inhaler from china with promising result ) will be approved by china body by end of Q3 2022. it will have great potential revenue once the inhaler version is approved because it is using the same vaccine approved by WHO.
康希諾生物に関するコメント
HSI Slides 342 Pts; Techs & Pharmas Gloom
Techs slid as the market continued to be watchful of the Sino-US relations:
$阿里巴巴集団(09988.HK)$ dived 3.2% to $84.1.
$テンセント(00700.HK)$ sank 1.9% to $338.4.
$美団点評(03690.HK)$ , $小米集団(01810.HK)$ , ...
Vaccine Makers Shoot up as CN Unveils Implementation Plan for Covid Vaccine Booster Shots
Hong Kong-listed vaccine makers, buoyed by the news, broadly shot up. $康希諾生物(06185.HK)$rose 6.6% to $90.6, on a volume of 9.0554 million shares, involving $801 million. $RECBIO-B(02179.HK)$ , $諾誠健華医薬(09969.HK)$ and ...
China announces measures to boost elderly vaccination
The notice said authorities should use multiple data points to accurately identify target groups for vaccination for the elderly.
$Hang Seng H-Share Index ETF(02828.HK)$$Hang Seng Index(800000.HK)$$人気中国関連株(BK2517.US)$$HKEX二次上場(BK1304.HK)$$AIM VACCINE(06660.HK)$$Guotai CNI Vaccines and biotechnology ETF(159643.SZ)$
it will have great potential revenue once the inhaler version is approved because it is using the same vaccine approved by WHO.
Bloomberg: Chinese mRNA Shot Beat Sinovac as Booster But Caused More Fevers
$シノバク・バイオテク(SVA.US)$ $復星医薬(02196.HK)$ $Shanghai Fosun Pharmaceutical(600196.SH)$ $CanSino Biologics Inc.(688185.SH)$ $康希諾生物(06185.HK)$ $Walvax Biotechnology(300142.SZ)$ $Chongqing Zhifei Biological Products(300122.SZ)$
https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued
まだコメントはありません